MSD wards off another Januvia challenger in India
This article was originally published in Scrip
Executive Summary
The train of domestic firms hoping to launch generic versions of Merck & Co's diabetes therapies Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride) on the Indian market continues to grow, the latest challenger being the relatively less known, Gujarat-based Olcare Laboratories.